COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Oral Oxycodone After Major Cardiac Surgery

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01816581
Recruitment Status : Completed
First Posted : March 22, 2013
Last Update Posted : March 26, 2014
Information provided by (Responsible Party):
Kurt Rutzler, Medical University of Vienna

Brief Summary:

Postoperative pain and analgesic treatment still remains a challenge in daily perioperative medicine. Skin incisions, intraoperative tissue retraction and -dissection, intravasal cannulations and drainages, sternotomy and pericardiotomy are the most important reasons for postoperative pain. Poorly controlled pain can contribute directly or indirectly to postoperative complications, such as myocardial ischemia, pulmonary dysfunction like hypoventilation, pneumonia and atelectasis, a delayed return of gastrointestinal function and decreased mobility. In addition, prolonged acute pain also results in chronic pain.

Opioids are internationally recognized as the golden standard in the treatment of acute postoperative pain. On one side, the high potency of opioids in pain relief is clearly undisputed, but on the other hand, the administration of opioids is associated with nausea, vomiting, sedation and with the development of bowel dysfunction, which encompasses symptoms including bloating, abdominal spasm, cramps and constipation. Opioid-induced constipation is a frequently reported adverse effect and sometimes requires discontinuation of therapy, which results in analgesic under-treatment, severely impairing quality of life. However, there are many different regimes for the treatment of postoperative pain using opioids. Patient-controlled analgesia (PCA) using morphine is widely used, but requires trained staff and expensive equipment. Once patients are able to tolerate oral medications, the oral route is preferred postoperatively because it is more convenient, noninvasive and less expensive.

Condition or disease Intervention/treatment Phase
Heart; Dysfunction Postoperative, Cardiac Surgery Drug: Targin Drug: Oxynorm Drug: Morphine Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 50 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Prospective, Randomized Clinical Pilot Study: Oral Opiate Targin In Treatment Of Postoperative Pain After Major Cardiac Surgery
Study Start Date : July 2011
Actual Primary Completion Date : May 2012
Actual Study Completion Date : March 2013

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Heart Surgery

Arm Intervention/treatment
Active Comparator: Targin/OxyNorm
Patients randomized to this study arm will receive Targin as basis pain medication and additional OxyNorm (Oxycodone), if requested by the patients.
Drug: Targin
Other Name: Oxycodonhydrochlorid and naloxone hydrochloride dihydrate

Drug: Oxynorm
Other Name: oral medication consisting of Oxycodonhydrochlorid

Active Comparator: PCA
Patients randomized to this group will receive a PCA pump with morphine. The basic rate is 0.3 mg/h. Patients will be allowed to administer 1 mg each five minutes after a vesting period of five minutes, if subjectively needed.
Drug: Morphine

Primary Outcome Measures :
  1. total opioid dosage in terms of so-called morphine equivalents [ Time Frame: 3 days ]
    total administrated opioid dosage during 3 days after surgery

Secondary Outcome Measures :
  1. VAS pain score [ Time Frame: 3 days ]
    Pain Scores on the Visual Analog Scale (0-100)

  2. level of sedation [ Time Frame: 3 days ]
    Level of Sedation using the Ramsey Sedation Score.

  3. rate of spontaneous breathing [ Time Frame: 3 days ]
    spontaneous breathing rate per minute

  4. possible side effects [ Time Frame: 3 days ]
    open documentation of any side effects like dizziness, vomiting, allergic reaction

  5. in hospital stay [ Time Frame: 1 month ]
  6. ICU stay [ Time Frame: 1 month ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 90 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age from 18 to 90 years
  • ASA physical status 1-3
  • Elective major cardiac surgery requiring sternotomy
  • Oral and written consent
  • Postoperative extubation within four hours after arrival at the ICU
  • Cognitive ability in the use of the PCA pump and the VAS

Exclusion Criteria:

  • Chronic use of opioids in the last three months
  • Chronic use of tranquilizer or pain medications
  • Hypersensitivity against opioids
  • Use of monoamine oxidase inhibitors in the last two weeks before surgery
  • Alcohol or drug abuse
  • Renal dysfunction (GFR < 30 or necessity of dialysis)
  • Liver Dysfunction defined as Child-Pugh-Score 7-15
  • Ejection fraction (EF< 40%)
  • Malabsorption syndrome
  • Neurologic or cognitive dysfunction
  • Pregnancy
  • Participation in another clinical trial
  • Severe respiratory depression with hypoxia and/or hypercapnia
  • Severe chronic obstructive pulmonary disease
  • Severe bronchial asthma
  • Non-opioid induced paralytic ileus
  • Risk of seizures

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01816581

Layout table for location information
Medical University Vienna
Vienna, Austria, 1090
Sponsors and Collaborators
Medical University of Vienna
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Kurt Rutzler, senior staff physician, Medical University of Vienna Identifier: NCT01816581    
Other Study ID Numbers: 1043/2010
First Posted: March 22, 2013    Key Record Dates
Last Update Posted: March 26, 2014
Last Verified: March 2014
Additional relevant MeSH terms:
Layout table for MeSH terms
Analgesics, Opioid
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents
Narcotic Antagonists